Cancer drug RVU120 gets extended trial for ongoing patients
NCT ID NCT06987058
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients can stay on treatment. Participants must have completed at least 5 cycles in the parent study and have no other available options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RVU120 (a drug that blocks certain proteins in cancer cells)
What this could lead to
If successful, this study could show that long-term RVU120 treatment is safe and helps control advanced solid tumors, AML, or high-risk MDS.
What could go wrong
This is a small rollover study (10 people) with no control group, so results may not apply broadly. Side effects are possible, and the drug may stop working over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
Contact
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80-214, Poland
Contact